Significant survival gains with atezolizumab vs docetaxel for non-small-cell lung cancer

The first phase III study of PD-L1 inhibitor  atezolizumab in previously-treated non-small-cell lung cancer has seen significant improvements in survival compared to standard chemotherapy, researchers report.
Source: Feed4

Leave a Reply

Your email address will not be published. Required fields are marked *